MCID: BLD008
MIFTS: 37

Bladder Carcinoma in Situ

Categories: Blood diseases, Cancer diseases, Genetic diseases, Nephrological diseases, Rare diseases

Aliases & Classifications for Bladder Carcinoma in Situ

MalaCards integrated aliases for Bladder Carcinoma in Situ:

Name: Bladder Carcinoma in Situ 12 15
Flat Cis of the Urinary Bladder 12
Carcinoma in Situ of Bladder 12
Bladder Ca in Situ 12

Classifications:



External Ids:

Disease Ontology 12 DOID:9053
ICD9CM 36 233.7
NCIt 51 C3644
SNOMED-CT 69 92546004
ICD10 34 D09.0
UMLS 74 C0154091

Summaries for Bladder Carcinoma in Situ

Disease Ontology : 12 An in situ carcinoma that is located in the bladder.

MalaCards based summary : Bladder Carcinoma in Situ, also known as flat cis of the urinary bladder, is related to bladder cancer and gall bladder carcinoma in situ. An important gene associated with Bladder Carcinoma in Situ is CCND3 (Cyclin D3), and among its related pathways/superpathways are DNA Damage Response and Cell cycle. The drugs BCG vaccine and Vaccines have been mentioned in the context of this disorder. Affiliated tissues include testes and the bladder.

Related Diseases for Bladder Carcinoma in Situ

Diseases in the Bladder Cancer family:

Bladder Carcinoma in Situ

Diseases related to Bladder Carcinoma in Situ via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 149)
# Related Disease Score Top Affiliating Genes
1 bladder cancer 29.5 CDKN2A KRT19 TP53 UPK2
2 gall bladder carcinoma in situ 12.4
3 in situ carcinoma 10.6
4 splenic diffuse red pulp small b-cell lymphoma 10.3 CCND3 TP53
5 retroperitoneum carcinoma 10.3 CDKN2A UPK2
6 keratinizing squamous cell carcinoma 10.2 CDKN2A TP53
7 spitz nevus 10.2 CDKN2A TP53
8 vulva squamous cell carcinoma 10.2 CDKN2A TP53
9 thyroid lymphoma 10.2 CDKN2A TP53
10 bartholin's gland disease 10.2 CDKN2A TP53
11 anal squamous cell carcinoma 10.2 CDKN2A TP53
12 megaesophagus 10.2 CDKN2A TP53
13 gastric adenosquamous carcinoma 10.2 CDKN2A TP53
14 anogenital venereal wart 10.2 CDKN2A TP53
15 cervix uteri carcinoma in situ 10.2 CDKN2A TP53
16 uterus carcinoma in situ 10.2 CDKN2A TP53
17 oral leukoplakia 10.2 CDKN2A TP53
18 gastric diffuse adenocarcinoma 10.2 KRT7 UPK2
19 bile duct adenoma 10.2 CDKN2A KRT7
20 inverted transitional papilloma 10.2 CDKN2A KRT7
21 meningeal melanomatosis 10.2 CDKN2A TP53
22 suppressor of tumorigenicity 3 10.2 CDKN2A TP53
23 dedifferentiated liposarcoma 10.2 CDKN2A TP53
24 penile disease 10.2 CDKN2A TP53
25 vulval paget's disease 10.2 CDKN2A KRT7
26 adenoid basal cell carcinoma 10.2 CDKN2A KRT7
27 endocervical carcinoma 10.2 CDKN2A KRT7
28 nasal cavity cancer 10.2 CDKN2A KRT7
29 vulva adenocarcinoma 10.2 CDKN2A KRT7
30 cervix small cell carcinoma 10.2 CDKN2A TP53
31 anal canal carcinoma 10.2 CDKN2A KRT7
32 verrucous carcinoma 10.2 CDKN2A TP53
33 malignant spiradenoma 10.2 KRT7 TP53
34 spiradenoma 10.2 KRT7 TP53
35 vulvar intraepithelial neoplasia 10.2 KRT7 TP53
36 tongue disease 10.2 CDKN2A TP53
37 mucinous bronchioloalveolar adenocarcinoma 10.2 CDKN2A KRT7
38 well-differentiated liposarcoma 10.2 CDKN2A KRT7
39 optic nerve neoplasm 10.2 CDKN2A TP53
40 papillary serous adenocarcinoma 10.2 KRT7 TP53
41 nasal cavity squamous cell carcinoma 10.2 CDKN2A KRT7
42 female reproductive endometrioid cancer 10.2 KRT7 TP53
43 prostate squamous cell carcinoma 10.2 KRT7 TP53
44 intrahepatic bile duct adenoma 10.2 KRT19 KRT7
45 anal gland adenocarcinoma 10.2 KRT19 KRT7
46 pleomorphic carcinoma 10.2 KRT7 TP53
47 proliferating trichilemmal cyst 10.2 KRT19 KRT7
48 cervical adenosquamous carcinoma 10.1 CDKN2A KRT7
49 anus adenocarcinoma 10.1 KRT19 KRT7
50 renal pelvis adenocarcinoma 10.1 KRT19 KRT7

Graphical network of the top 20 diseases related to Bladder Carcinoma in Situ:



Diseases related to Bladder Carcinoma in Situ

Symptoms & Phenotypes for Bladder Carcinoma in Situ

Drugs & Therapeutics for Bladder Carcinoma in Situ

Drugs for Bladder Carcinoma in Situ (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 17)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
BCG vaccine Investigational Phase 3,Phase 1
2 Vaccines Phase 3,Phase 1
3 Adjuvants, Immunologic Phase 3,Phase 1
4 Immunologic Factors Phase 3,Phase 2,Phase 1
5 Pharmaceutical Solutions Phase 3,Phase 1
6
Atezolizumab Approved, Investigational Phase 2 1380723-44-3
7 Antibodies Phase 2,Phase 1
8 Antibodies, Monoclonal Phase 2,Phase 1
9 Immunoglobulins Phase 2,Phase 1
10
Erlotinib Hydrochloride Phase 2 183319-69-9 176871
11 Protein Kinase Inhibitors Phase 2
12
Pembrolizumab Approved Phase 1 1374853-91-4
13
Altretamine Approved Phase 1 645-05-6 2123
14 Antineoplastic Agents, Immunological Phase 1
15
Valrubicin Approved 56124-62-0 41744
16
Calcium Approved, Nutraceutical 7440-70-2 271
17 Calcium, Dietary

Interventional clinical trials:


# Name Status NCT ID Phase Drugs
1 S1602: Different Strains of BCG With or Without Vaccine in High Grade Non- Muscle Invasive Bladder Cancer Recruiting NCT03091660 Phase 3
2 Atezolizumab in Treating Patients With Recurrent BCG-Unresponsive Non-muscle Invasive Bladder Cancer Recruiting NCT02844816 Phase 2 Atezolizumab
3 Erlotinib Hydrochloride in Treating Participants With Muscle Invasive or Recurrent Urothelial Cancer Active, not recruiting NCT00749892 Phase 2 Erlotinib Hydrochloride
4 Pembrolizumab and BCG Solution in Treating Patients With Recurrent Non-Muscle-Invasive Bladder Cancer Recruiting NCT02808143 Phase 1
5 sEphB4-HSA in Treating Participants With BCG-Unresponsive or Refractory Bladder Cancer Not yet recruiting NCT03552796 Phase 1
6 Study of CP-675,206 in Bacillus Calmette-Guerin (BCG)-Resistant Bladder Cancer Withdrawn NCT00880854 Phase 1 BCG and CP-675,206
7 Talimogene Laherparepvec in Treating Patients With Non-Muscle Invasive Bladder Transitional Cell Carcinoma Withdrawn NCT03430687 Phase 1
8 Retrospective Chart Review of Valstar Completed NCT01304173
9 Robotic or Open Radical Cystectomy in Treating Patients With Bladder Cancer Recruiting NCT02699853 Not Applicable
10 Ultrasound and Biomarker Tests in Predicting Cancer Aggressiveness in Tissue Samples of Patients With Bladder Cancer Recruiting NCT02494635

Search NIH Clinical Center for Bladder Carcinoma in Situ

Genetic Tests for Bladder Carcinoma in Situ

Anatomical Context for Bladder Carcinoma in Situ

MalaCards organs/tissues related to Bladder Carcinoma in Situ:

42
Testes

The Foundational Model of Anatomy Ontology organs/tissues related to Bladder Carcinoma in Situ:

20
The Bladder

Publications for Bladder Carcinoma in Situ

Articles related to Bladder Carcinoma in Situ:

(show all 30)
# Title Authors Year
1
Educational Case: Bladder Carcinoma In Situ. ( 30140732 )
2018
2
Safe and effective administration of BCG for bladder carcinoma in situ after umbilical cord blood stem cell transplantation. ( 28796929 )
2017
3
Long-term outcome of intravesical bacillus Calmette-GuAcrin therapy with maintenance for urinary bladder carcinoma in situ: About 47 cases. ( 28994883 )
2016
4
Are cystoscopy and urinary cytology sufficient to identify candidates for subsequent biopsy after bacillus Calmette-GuAcrin treatment in patients with bladder carcinoma in situ? ( 25660358 )
2015
5
Bladder carcinoma in situ (CIS) in Australia: a rising incidence for an under-reported malignancy. ( 23573811 )
2013
6
Intravesical valrubicin in patients with bladder carcinoma in situ and contraindication to or failure after bacillus Calmette-GuAcrin. ( 22575238 )
2013
7
A common MicroRNA signature consisting of miR-133a, miR-139-3p, and miR-142-3p clusters bladder carcinoma in situ with normal umbrella cells. ( 23410519 )
2013
8
Prognostic effect of urinary bladder carcinoma in situ on clinical outcome of subsequent upper tract urothelial carcinoma. ( 21167566 )
2011
9
Factors affecting valrubicin response in patients with bacillus Calmette-GuAcrin-refractory bladder carcinoma in situ. ( 21566413 )
2011
10
Clinical outcome of primary versus secondary bladder carcinoma in situ. ( 20620399 )
2010
11
Cyclin D3 gene amplification in bladder carcinoma in situ. ( 20821231 )
2010
12
Clinical outcomes of primary bladder carcinoma in situ in a contemporary series. ( 20546806 )
2010
13
Enhancing detection of bladder carcinoma in situ by 3-dimensional optical coherence tomography. ( 20723922 )
2010
14
The natural history of bladder carcinoma in situ after initial response to bacillus Calmette-GA_erin immunotherapy. ( 18440839 )
2009
15
Increased infiltration of tumor associated macrophages is associated with poor prognosis of bladder carcinoma in situ after intravesical bacillus Calmette-Guerin instillation. ( 19237175 )
2009
16
Enhanced formation of nitric oxide in bladder carcinoma in situ and in BCG treated bladder cancer. ( 16517187 )
2006
17
Bladder carcinoma in situ in 2003: state of the art. ( 14733997 )
2004
18
Fluorescence detection of flat bladder carcinoma in situ after intravesical instillation of hypericin. ( 10893582 )
2000
19
Oral bropirimine immunotherapy of bladder carcinoma in situ after prior intravesical bacille Calmette-GuAcrin. ( 9495702 )
1998
20
Primary bladder carcinoma in situ: assessment of early BCG response as a prognostic factor. ( 9643664 )
1998
21
Upper urinary tract involvement in patients with bladder carcinoma in situ (Tis): its impact on management. ( 9123696 )
1997
22
Bacillus Calmette-Guerin therapy for bladder carcinoma in situ: use in a clinical setting. ( 9239141 )
1997
23
Extravesical involvement in patients with bladder carcinoma in situ: biological and therapy implications. ( 8583601 )
1996
24
Treatment of bladder carcinoma in situ with mitomycin C: long-term follow-up. ( 8002217 )
1994
25
Morphometric and immunohistochemical characterization of bladder carcinoma in situ and its preneoplastic lesions. ( 1425837 )
1992
26
Long-term complete remission in bladder carcinoma in situ with intravesical TICE bacillus Calmette Guerin. Overview analysis of six phase II clinical trials. ( 1836081 )
1991
27
Presence of human papillomavirus type 16 genome in bladder carcinoma in situ of a patient with mild immunodeficiency. ( 2847865 )
1988
28
Value of random endoscopic biopsy in the diagnosis of bladder carcinoma in situ. ( 3609088 )
1987
29
The use of bacillus Calmette-Guerin in the therapy of bladder carcinoma in situ. ( 3892049 )
1985
30
Bladder carcinoma in situ: conservative versus aggressive approach. ( 6473399 )
1984

Variations for Bladder Carcinoma in Situ

Expression for Bladder Carcinoma in Situ

Search GEO for disease gene expression data for Bladder Carcinoma in Situ.

Pathways for Bladder Carcinoma in Situ

GO Terms for Bladder Carcinoma in Situ

Biological processes related to Bladder Carcinoma in Situ according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 replicative senescence GO:0090399 8.62 CDKN2A TP53

Molecular functions related to Bladder Carcinoma in Situ according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 disordered domain specific binding GO:0097718 8.62 CDKN2A TP53

Sources for Bladder Carcinoma in Situ

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....